A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Bristol-Myers Squibb
Related studies linked through entity extraction aliases.
Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis
- Status
- COMPLETED
- Phase
- PHASE2
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
- Status
- TERMINATED
- Phase
- PHASE1
Surgical Nivolumab And Ipilimumab For Recurrent GBM
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma
- Status
- TERMINATED
- Phase
- PHASE1
Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant
- Status
- WITHDRAWN
- Phase
- PHASE2
The IRMI-FMT Trial
- Status
- TERMINATED
- Phase
- NA
Accelerated Radio-Immunotherapy for Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab+Ipilimumab+RT in MSS mCRC
- Status
- UNKNOWN
- Phase
- PHASE2
Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities
- Status
- TERMINATED
- Phase
- PHASE2
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male Participants
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
- Status
- COMPLETED
- Phase
- PHASE2